nach oben

Erschienen in:

19.04.2022 | Oropharynxkarzinom | Zertifizierte Fortbildung

Steigende Inzidenz

HPV-assoziierte Oropharynxkarzinome: Einschätzung des Erkrankungsrisikos

verfasst von: Dr. med. Christian Jacobi, Dr. med. Ivelina Stoycheva

Erschienen in: HNO Nachrichten | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Auszug

Die Zahl der HPV-assoziierten Oropharynxkarzinome steigt weltweit. Und auch die Berichterstattung in den Medien mit einem Bezug auf die sexuelle Übertragbarkeit von HPV nimmt zu. Das führt oft zu Verunsicherung bei Patienten. Daher ist es wichtig, die potenziellen Risikofaktoren und die Zahlen zum Erkrankungsrisiko zu kennen. So können Sie alle Fragen kompetent einordnen und beantworten. …

Zentrum für Krebsregisterdaten. Krebs in Deutschland für 2017/2018, 13. Ausgabe. Berlin: Robert Koch-Institut; 2021

S3-Leitlinie "Impfprävention HPV-assoziierter Neoplasien. AWMF-Registernr. 082-002; Stand Mai 2020

Jansen L et al. Mundhöhlen- und Pharynxkarzinome: Inzidenz, Mortalität und Überleben in Deutschland. Bundesgesundheitsbl. 2021; 64:941-50

Plummer M et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4:e609-16

Gillison ML et al. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015;33:3235-42

Tota JE et al. Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Prev Med. 2011; 53(Suppl 1):S12-21

Senkomago V et al. Human Papillomavirus-Attributable Cancers — United States, 2012-2016. MMWR Morb Mortal Wkly Rep. 2019;68:724-8

Vlachea P. Etablierung eines RT-PCR-Assays zum Nachweis von E6/E7-Onkogen-Transkripten aus archiviertem Paraffingewebe von Plattenepithelkarzinomen der Kopf-Hals-Region [dissertation]. München: LMU; 2021

Buttmann-Schweiger N et al. Cancer incidence in Germany attributable to human papillomavirus in 2013. BMC Cancer. 2017;17:682

10.

Stanley M. Perspective: Vaccinate boys too. Nature. 2012;488:S10

11.

Stein AP et al. Prevalence of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma in the United States Across Time. Chem Res Toxicol. 2014;27:462-9

12.

Ndiaye C et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15:1319-31

13.

Mehanna H et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck, vol. 35, no. 5, pp. 747-755, May 2013, doi: 10.1002/hed.22015.

14.

Rettig E et al. The role of sexual behavior in head and neck cancer: implications for prevention and therapy. Expert Rev Anticancer Ther. 2015;15:35-49

15.

Van Dyne EA et al. Trends in Human Papillomavirus-Associated Cancers — United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2018;67:918-24

16.

Tota JE et al. Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals. J Clin Oncol. 2019;37:1538-46

17.

Chaturvedi AK et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294-301

18.

Braakhuis BJM et al. Incidence and survival trends of head and neck squamous cell carcinoma in the Netherlands between 1989 and 2011. Oral Oncol. 2014;50:670-5

19.

Prigge ES et al. p16(INK4a) /Ki-67 co-expression specifically identifies transformed cells in the head and neck region. Int J Cancer. 2015;136:1589-99

20.

Wittekindt C et al. Oropharynxkarzinome: Wenn humane Papillomviren die Tumorauslöser sind. Dtsch Arztebl. 2018;115:[10]

21.

Smith EM et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer. 2004;108:766-72

22.

Kreimer AR et al. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis. 2010;37:386-91

23.

Beachler DC et al. Natural History of Anal vs Oral HPV Infection in HIV-Infected Men and Women. J Infect Dis. 2013;208:330-9

24.

Lang Kuhs KA et al. Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis. Cancer Epidemiol Biomarkers Prev. 2015;24:683-9

25.

Steinau M et al. Prevalence of Cervical and Oral Human Papillomavirus Infections Among US Women. J Infect Dis. 2014;209:1739-43

26.

Kreimer AR et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet. 2013;382:877-87

27.

Wittekindt C et al. HPV - Das andere Kopf-Hals-Karzinom. Laryngo-Rhino-Otologie. 2018;97:S48-S81

28.

Chesson HW et al. The Estimated Lifetime Probability of Acquiring Human Papillomavirus in the United States. Sex Transm Dis. 2014;41:660-4

29.

D'Souza G et al. Understanding personal risk of oropharyngeal cancer: risk-groups for oncogenic oral HPV infection and oropharyngeal cancer. Ann Oncol. 2017;28:3065-9

30.

Kero K et al. Smoking increases oral HPV persistence among men: 7-year follow-up study. Eur J Clin Microbiol Infect Dis. 2014;33:123-33

31.

Rautava J et al. Prevalence, Genotype Distribution and Persistence of Human Papillomavirus in Oral Mucosa of Women: A Six-Year Follow-Up Study. PLoS One. 2012;7,:e42171

32.

Gillison ML et al. Prevalence of Oral HPV Infection in the United States, 2009-2010. JAMA. 2012;307:693-703

33.

Chaturvedi AK et al. Incidence Trends for Human Papillomavirus-Related and -Unrelated Oral Squamous Cell Carcinomas in the United States. J Clin Oncol. 2008;26:612-9

34.

Herrero R et al. Human Papillomavirus and Oral Cancer: The International Agency for Research on Cancer Multicenter Study. J Natl Cancer Inst. 2003;95:1772-83

35.

Drake VE et al. Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer. Cancer. 2021;127:1029-38

36.

D'Souza G et al. Case-Control Study of Human Papillomavirus and Oropharyngeal Cancer. N Engl J Med. 2007;356:1944-56

37.

Farsi NJ et al. Sexual behaviours and head and neck cancer: A systematic review and meta-analysis. Cancer Epidemiol. 2015;39:1036-46

38.

Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32:16-24

39.

Heck JE et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol. 2010;39:166-81

40.

Gillison ML et al. Distinct Risk Factor Profiles for Human Papillomavirus Type 16-Positive and Human Papillomavirus Type 16-Negative Head and Neck Cancers.," J natl Cancer Inst. 2008;100:407-20

41.

Manhart LE, Koutsky LA. Do Condoms Prevent Genital HPV Infection, External Genital Warts, or Cervical Neoplasia? Sex Transm Dis. 2002;29:725-35

42.

Nielson CM et al. Consistent Condom Use Is Associated with Lower Prevalence of Human Papillomavirus Infection in Men. J Infect Dis. 2010;202:445-51

43.

Kjaer SK et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev. 2001;10:101-6

44.

Beachler DC et al. Risk Factors for Acquisition and Clearance of Oral Human Papillomavirus Infection Among HIV-Infected and HIV-Uninfected Adults Am J Epidemiol. 2015;181:40-53

45.

Giuliano AR et al. EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015;136:2752-60

46.

D'Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med. 2011;53(Suppl 1):S5-S11

47.

Safaeian M et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst. 2010;102:1653-62

48.

Ho GYF et al. Risk Factors for Subsequent Cervicovaginal Human Papillomavirus (HPV) Infection and the Protective Role of Antibodies to HPV-16 Virus-Like Particles. J Infect Dis. 2002;186:737-42

49.

Herrero R et al. Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. PLoS One. 2013;8:e68329

50.

Kreimer AR et al. Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer. J Clin Oncol. 2013;31:2708-15

51.

Lu B et al. Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men. Cancer Res. 2021;72:676-85

52.

D'Souza G et al. Oral Human Papillomavirus (HPV) Infection in HPV-Positive Patients With Oropharyngeal Cancer and Their Partners. J Clin Oncol. 2014;32:2408-15

53.

Vogt SL et al. Concordant Oral-Genital HPV Infection in South Africa Couples: Evidence for Transmission. Front. Oncol. 2013;3:303

54.

Rintala M et al. Natural history of oral papillomavirus infections in spouses: A prospective Finnish HPV Family Study. J Clin Virol. 2006;35:89-94

55.

Mirghani H et al. Is there an increased risk of cancer among spouses of patients with an HPV-related cancer: A systematic review. Oral Oncol. 2017;67:138-45

56.

Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020;17:864-78

57.

Gillison ML et al. Human Papillomavirus and Diseases of the Upper Airway: Head and Neck Cancer and Respiratory Papillomatosis. Vaccine. 2021;30(Supp 5):F34-54

58.

Chi AC et al. Oral cavity and oropharyngeal squamous cell carcinoma-an update. CA Cancer J Clin. 2015;65:401-21

59.

Elrefaey S et al. HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital. 2014;34:299-309

60.

Evans M et al. Human Papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population. BMC Cancer. 2013;13:220

61.

Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. Cancer. 2017;123:2219-29

Titel: Steigende Inzidenz
HPV-assoziierte Oropharynxkarzinome: Einschätzung des Erkrankungsrisikos
verfasst von: Dr. med. Christian Jacobi
Dr. med. Ivelina Stoycheva
Publikationsdatum: 19.04.2022
Verlag: Springer Medizin
Schlagwörter: Oropharynxkarzinom
Humane Papillomviren
Erschienen in: HNO Nachrichten / Ausgabe 2/2022
Print ISSN: 0177-1000
Elektronische ISSN: 2198-6533
DOI: https://doi.org/10.1007/s00060-022-7734-8

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Allergologie für die Praxis aufbereitet

Aktuelle Daten bestätigen Wirksamkeit der allergenspezifischen Immuntherapie

Duale Rezeptorblockade zur gezielten Behandlung der CRSwNP

Polymedikation im Alter

Darf die Einwilligung sofort nach dem Aufklärungsgespräch unterschrieben werden?

Tinnitus-App auf Platz eins der Verordnungen